These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: The Prognostic and Clinicopathological Significance of IGF-1R in NSCLC: a Meta-Analysis.
    Author: Zhao J, Shi X, Wang T, Ying C, He S, Chen Y.
    Journal: Cell Physiol Biochem; 2017; 43(2):697-704. PubMed ID: 28946136.
    Abstract:
    BACKGROUND/AIMS: Accumulating studies have reported that IGF-1R (Insulin-like growth factor-1 receptor) is aberrantly expressed in NSCLC (non-small cell lung cancer), but the role of IGF-1R in NSCLC remains controversial. The present paper assessed the precise role of IGF-1R in NSCLC. METHODS: We comprehensively searched PubMed, EMBASE, and Web of Science in March 2017. Combined HRs and ORs were used to evaluate the prognostic and clinicopathological significance of IGF-1R in NSCLC respectively. RESULTS: A total of 10 eligible studies including 8 on overall survival, and 10 on clinicopathological features were identified from the databases. The results showed that high expression of IGF-1R was associated with shorter OS (overall survival) of NSCLC patients (pooled HR 1.17,95 % CI 1.00-1.36). In addition, we found that IGF-1R was related to smoking status (OR=1.82, 95 % CI=1.35-2.44) and IGF-1R tended to be highly expressed in SCC (squamous cell carcinoma) (OR=3.40 95 % CI: 1.95-5.95). CONCLUSIONS: In summary, this meta-analysis revealed that high expression of IGF-1R was associated with poor prognosis in NSCLC.
    [Abstract] [Full Text] [Related] [New Search]